Compugen Ltd. Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) announced today that pre-clinical findings presented at the 3rd European Congress of Immunology provide additional support for the potential of CGEN-15001 to effectively treat autoimmune disease. Mode of action studies for CGEN-15001 demonstrated both the active suppression of pathogenic immune responses and the reestablishment of immune balance by increasing anti-inflammatory mediators and promoting inducible regulatory T cells (iTregs). Modulation of iTregs is considered an extremely promising approach for treatment of autoimmunity and cancer, and therefore has been the focus of intense industry and academic research in recent years.